The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Prevention of High-Dose Chemotherapy–Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme Inhibition
Abstract
Background— An increase in troponin I soon after high-dose chemotherapy (HDC) is a strong predictor of poor cardiological outcome in cancer patients. This finding has important clinical implications and provides a rationale for the development of prophylactic strategies for preventing cardiotoxicity. Angiotensin-converting enzyme inhibitors slow the progression of left ventricular dysfunction in different clinical settings, but their role in the prevention of cardiotoxicity has never been investigated. Methods and Results— Of the 473 cancer patients evaluated, 114 (72 women; mean age, 45±12 years) who showed a troponin I increase soon after HDC were randomized to receive (angiotensin-converting enzyme inhibitor group; 20 mg/d; n=56) or not to receive (control subjects; n=58) enalapril. Treatment was started 1 month after HDC and continued for 1 year. Cardiological evaluation was performed at baseline and at 1, 3, 6, and 12 months after HDC. The primary end point was an absolute decrease >10 percent units in left ventricular ejection fraction, with a decline below the normal limit value. A significant reduction in left ventricular ejection fraction and an increase in end-diastolic and end-systolic volumes were observed only in untreated patients. According to the Kaplan-Meier analysis, the incidence of the primary end point was significantly higher in control subjects than in the angiotensin-converting enzyme inhibitor group (43% versus 0%; P <0.001). Conclusions— In high-risk, HDC-treated patients, defined by an increased troponin I value, early treatment with enalapril seems to prevent the development of late cardiotoxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Recommendations for Quantitation of the Left Ventricle by Two-Dimensional Echocardiography
Schiller, N. B., Shah, P. M., Crawford, M., DeMaria, A., Devereux, R., Feigenbaum, H., Gutgesell, H., Reichek, N., Sahn, D., Schnittger, I., et al. (1989) · Journal of the American Society of Echocardiography · doi:10.1016/s0894-7317(89)80014-8 · Cited by 8,121
ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult
Hunt, S. A. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.08.022 · Cited by 4,154
(1992) · New England Journal of Medicine · doi:10.1056/nejm199209033271003 · Cited by 3,725
Risk Factors for Doxorubicin-lnduced Congestive Heart Failure
VON HOFF, D. D., LAYARD, M. W., BASA, P., DAVIS, H. L., VON HOFF, A. L., ROZENCWEIG, M., & MUGGIA, F. M. (1979) · Annals of Internal Medicine · doi:10.7326/0003-4819-91-5-710 · Cited by 2,391
Cardinale, D., Sandri, M. T., Colombo, A., Colombo, N., Boeri, M., Lamantia, G., Civelli, M., Peccatori, F., Martinelli, G., Fiorentini, C., et al. (2004) · Circulation · doi:10.1161/01.cir.0000130926.51766.cc · Cited by 955
Self-citationCardiovascular Complications of Cancer Therapy: Diagnosis, Pathogenesis, and Management
Yeh, E. T. H., Tong, A. T., Lenihan, D. J., Yusuf, S. W., Swafford, J., Champion, C., Durand, J.-B., Gibbs, H., Zafarmand, A. A., & Ewer, M. S. (2004) · Circulation · doi:10.1161/01.cir.0000133187.74800.b9 · Cited by 843
Anthracycline-Induced Cardiotoxicity
Shan, K., Lincoff, A. M., & Young, J. B. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-1-199607010-00008 · Cited by 749
Cardiotoxicity of Chemotherapeutic Agents: Incidence, Treatment and Prevention
Pai, V. B., & Nahata, M. C. (2000) · Drug Safety · doi:10.2165/00002018-200022040-00002 · Cited by 729
Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy
Cardinale, D., Sandri, M. T., Martinoni, A., Tricca LabTech, A., Civelli, M., Lamantia, G., Cinieri, S., Martinelli, G., Cipolla, C. M., & Fiorentini, C. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00748-8 · Cited by 551
Self-citationThe Adult With Congenital Heart Disease
Warnes, C. A. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.02.083 · Cited by 480
Wouters, K. A., Kremer, L. C. M., Miller, T. L., Herman, E. H., & Lipshultz, S. E. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05759.x · Cited by 453
Travis, L. B., Rabkin, C. S., Brown, L. M., Allan, J. M., Alter, B. P., Ambrosone, C. B., Begg, C. B., Caporaso, N., Chanock, S., DeMichele, A., et al. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj001 · Cited by 342
(2004) · European Heart Journal · doi:10.1016/j.ehj.2004.06.003 · Cited by 331
Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy
Cardinale, D., Sandri, M. T., Martinoni, A., Borghini, E., Civelli, M., Lamantia, G., Cinieri, S., Martinelli, G., Fiorentini, C., & Cipolla, C. M. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf170 · Cited by 313
Self-citationSilber, J. H., Cnaan, A., Clark, B. J., Paridon, S. M., Chin, A. J., Rychik, J., Hogarty, A. N., Cohen, M. I., Barber, G., Rutkowski, M., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.022 · Cited by 299
Clinical Cardiac Tolerability of Trastuzumab
Perez, E. A., & Rodeheffer, R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.01.120 · Cited by 280
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for High-Risk Breast Cancer
Rodenhuis, S., Bontenbal, M., Beex, L. V. A. M., Wagstaff, J., Richel, D. J., Nooij, M. A., Voest, E. E., Hupperets, P., van Tinteren, H., Peterse, H. L., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022794 · Cited by 258
Chemotherapy-Induced Cardiotoxicity: Current Practice and Prospects of Prophylaxis
Gharib, M. I., & Burnett, A. K. (2002) · European Journal of Heart Failure · doi:10.1016/s1388-9842(01)00201-x · Cited by 200
Preventive Effect of Erythropoietin on Cardiac Dysfunction in Doxorubicin-Induced Cardiomyopathy
Li, L., Takemura, G., Li, Y., Miyata, S., Esaki, M., Okada, H., Kanamori, H., Khai, N. C., Maruyama, R., Ogino, A., et al. (2006) · Circulation · doi:10.1161/circulationaha.105.568402 · Cited by 197
Cancer prevalence in European registry areas
Micheli, A., Mugno, E., Krogh, V., Quinn, M. J., Coleman, M., Hakulinen, T., Gatta, G., Berrino, F., & Capocaccia, R. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf127 · Cited by 195
Anthracycline-induced cardiomyopathy
KEEFE, D. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90193-9 · Cited by 169
Sandri, M. T., Cardinale, D. M., Zorzino, L., Passerini, R., Lentati, P., Martinoni, A., Martinelli, G., & Cipolla, C. M. (2003) · Clinical Chemistry · doi:10.1373/49.2.248 · Cited by 123
Self-citationSacco, G., Bigioni, M., Evangelista, S., Goso, C., Manzini, S., & Maggi, C. A. (2001) · European Journal of Pharmacology · doi:10.1016/s0014-2999(01)00782-8 · Cited by 113
El‐Aziz, M. A. A., Othman, A. I., Amer, M., & El-Missiry, M. A. (2001) · Journal of Applied Toxicology · doi:10.1002/jat.782 · Cited by 107
Captopril ameliorates myocardial and hematological toxicities induced by adriamycin
Al‐Shabanah, O. A., Mansour, M. A., El‐Kashef, H. A., & Al‐Bekairi, A. M. (1998) · IUBMB Life · doi:10.1080/15216549800202802 · Cited by 69
Tokudome, T., Mizushige, K., Noma, T., Manabe, K., Murakami, K., Tsuji, T., Nozaki, S., Tomohiro, A., & Matsuo, H. (2000) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-200009000-00012 · Cited by 66
Vaynblat, M., Shah, H. R., Bhaskaran, D., Ramdev, G., Davis, W. J., Cunningham, J. N., & Chiavarelli, M. (2002) · European Journal of Heart Failure · doi:10.1016/s1388-9842(02)00091-0 · Cited by 64
Bregni, M., Siena, S., Nicola, M. D., Dodero, A., Peccatori, F. A., Ravagnani, F., Danesini, G. M., Laffranchi, A., Bonadonna, G., & Gianni, A. M. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.2.628 · Cited by 32
Cited by
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001063 · Cited by 4,922
Lyon, A. R., López-Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J., Boriani, G., Cardinale, D., Cordoba, R., Cosyns, B., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac244 · Cited by 3,076
Self-citation2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.12.012 · Cited by 2,862
Zamorano, J. L., Lancellotti, P., Rodriguez Muñoz, D., Aboyans, V., Asteggiano, R., Galderisi, M., Habib, G., Lenihan, D. J., Lip, G. Y. H., Lyon, A. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw211 · Cited by 2,544
Zamorano, J. L., Lancellotti, P., Rodriguez Muñoz, D., Aboyans, V., Asteggiano, R., Galderisi, M., Habib, G., Lenihan, D. J., Lip, G. Y. H., Lyon, A. R., et al. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.654 · Cited by 1,795
Metadata
- Authors
- Cardinale, D., Colombo, A., Sandri, M. T., Lamantia, G., Colombo, N., Civelli, M., Martinelli, G., Veglia, F., Fiorentini, C., & Cipolla, C. M.
- Venue
- Circulation
- Published
- 2006-12-05
- Volume
- 114
- Issue
- 23
- Pages
- 2474-2481
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2109775164
- Cited by
- 1,026
- References
- 28
- FWCI
- 19.47
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.